Results 31 to 40 of about 10,699 (192)

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population [PDF]

, 2017
Acknowledgments The authors thank Derek Skinner (Cambridge Research Support Ltd, Oakington, Cambridge, UK) for assistance with data extraction.Peer reviewedPublisher ...
Gibson, Danny, Golam, Sarowar, Hillyer, Elizabeth V, Kerkhof, Marjan, Price, David B, Soriano, Joan B, Tran, Trung N   +6 more
core   +1 more source

Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE)

Clinical and Translational Allergy, 2022
Background Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation. The effects of these compound on the immunoglobulin (Ig)E T2 component are virtually
Marco Contoli, Pierachille Santus, Francesco Menzella, Cindy Rocchi, Dejan Radovanovic, Federico Baraldi, Chiara Martelli, Serena Casanova, Carlo Barbetta, Claudio Micheletto, Nicola Scichilone, Bianca Beghè, Elisiana Carpagnano, Alberto Papi   +13 more
doaj   +1 more source

Mepolizumab versus placebo for asthma [PDF]

, 2015
Background Mepolizumab is a human monoclonal antibody against interleukin-5 (IL-5), the main cytokine involved in the activation of eosinophils, which in turn causes airway inflammation.
Alvarez-Cuesta, Armentia, Ayars, Ayars, Ayres, Bel, Berger, Blanken, Blanken, Boever, Boulet, Bousquet, Bousquet, Braman, Brown, Bryant, Bryant, Buhl, Buhl, Buhl, Bush, Busse, Busse, Buttner, Caffarelli, Castro, Castro, Chandra, Chervinsky, Clavel, Corren, Corren, Cruz, Cullell-Young, Djukanovic, Ebner, Eckman, El-Nawawy, Fahy, Fahy, Finn, Flood-Page, Flood-Page, Flood-Page, Flood-Page, Frew, Fuhlbrigge, Garcia, Gauvreau, Gauvreau, Gauvreau, Gauvreau, Gevaert, Gibson, Gordon, Greenberg, Gupta, Haldar, Haldar, Haldar, Han, Hanania, Hanania, Hanania, Hill, Hodsman, Holgate, Hoshino, Humbert, Humbert, Humbert, Jacquemin, Jutel, Kandane-Rathnayake, Kang, Kay, Kips, Kon, Kopp, Kopp, Krishnan, Kulus, Lanier, Lanier, Laviolette, Leckie, Leynadier, Lizaso, Masoli, Massanari, Massanari, Mathur, Menzies-Gow, Menzies-Gow, Metzger, Milgrom, Milgrom, Modlin, Moss, Nair, Nair, Nair, Niven, Noga, Noga, Noonan, Oba, Oh, Ohashi, Ohman, Ohta, Ong, Ortega, Ortega, Parker, Patel, Pauli, Pavord, Pavord, Phipps, Piper, Prieto, Pui, Rensen, Rose, Sakamoto, Scheerens, Scheerens, Siergiejko, Silk, Silkoff, Simoes, Singh, Slavin, Soler, Sorkness, Sthoeger, Sugaya, Swanson, Szymaniak, Tanaka, Terr, Vignola, Wark, Wenzel, Wenzel, Wu, Zetterstrom, Zhu, Zielen   +149 more
core   +2 more sources

We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma [PDF]

, 2018
Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that ...
4,, BEGHE', Bianca, Fabbri, Lm3, Papi, A1   +3 more
core   +1 more source

Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy

Respiratory Medicine Case Reports, 2023
A 26-year-old female with steroid dependent eosinophilic asthma and nasal polyps who had successfully been treated with mepolizumab for 17 consecutive months with complete steroid withdrawal and symptoms control, stopped biologic treatment due to ...
Stylianos K. Vittorakis, Georgia Giannakopoulou, Konstantinos Samitas, Eleftherios Zervas   +3 more
doaj   +1 more source

Diagnosis and management of eosinophilic asthma: a US perspective. [PDF]

, 2014
Eosinophilic asthma is now recognized as an important subphenotype of asthma based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and ...
Doherty, Taylor A, Walford, Hannah H
core   +1 more source

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology, 2023
Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps.
Fan Zou, Chengyu Zhu, Siyu Lou, Zhiwei Cui, Dan Wang, Yingyong Ou, Li Wang, Junyou Chen, Yuanbo Lan   +8 more
doaj   +1 more source

Mepolizumab.

Australian prescriber
  +14 more sources

Nanoparticles in the treatment of chronic lung diseases [PDF]

, 2019
Nanoparticles, although considered a topic of modern medicine, actually have an interesting history. Currently, advances in nanomedicine hold great promise as drug carrier systems for sustained release and targeted delivery of diverse therapeutic agents.
Alexescu, Teodora G, Cosnarovici, Maria, Negrean, Vasile, Orasan, Olga H, Para, Ioana, Perne, Mirela G, Popovici, Ionela, Ruta, Victoria M, Tarmure, Simina, Todea, Doina A   +9 more
core   +2 more sources

Elevated mepolizumab levels in patients with severe asthma responsive to 1 year’s mepolizumab treatment

Journal of Allergy and Clinical Immunology: Global
Background: Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids.
Takayasu Nishimaki, MD, Hitoshi Sasano, MD, PhD, Sonoko Harada, PhD, Tomohito Takeshige, MD, PhD, Yuuki Sandhu, MD, PhD, Yuki Tanabe, MD, Kei Matsuno, MD, PhD, Tetsutaro Nagaoka, MD, PhD, Jun Ito, MD, PhD, Ryo Atsuta, MD, PhD, Mayu Ohuchi, PhD, Shigehiro Yagishita, MD, PhD, Akinobu Hamada, PhD, Kazuhisa Takahashi, MD, PhD, Norihiro Harada, MD, PhD   +14 more
doaj   +1 more source